Amgen Inc. (BMV:AMGN)

Market Cap	2.94T
Revenue (ttm)	658.47B
Net Income (ttm)	124.82B
Shares Out	n/a
EPS (ttm)	230.64
PE Ratio	23.56
Forward PE	14.23
Dividend	182.89 (3.42%)
Ex-Dividend Date	May 16, 2025

Volume	214
Average Volume	640
Open	5,342.00
Previous Close	5,321.42
Day's Range	5,342.00 - 5,342.00
52-Week Range	5,223.70 - 6,680.00
Beta	0.48
RSI	43.60
Earnings Date	Aug 4, 2025

About Amgen

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company’s principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet’s disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascul...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1980
• Employees: 28,000
• Stock Exchange: Mexican Stock Exchange
• Ticker Symbol: AMGN

Financial Performance

In 2024, Amgen's revenue was $33.42 billion, an increase of 18.57% compared to the previous year's $28.19 billion. Earnings were $4.09 billion, a decrease of -39.11%.

Financial numbers in USD